Welcome to our dedicated page for Biorestorative Therapies SEC filings (Ticker: BRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioRestorative Therapies filings document the regulatory record of a Nevada regenerative medicine company listed on the Nasdaq Capital Market under BRTX. Its disclosures cover BRTX-100 clinical development for chronic lumbar disc disease, the ThermoStem metabolic program, the BioCosmeceutical platform, operating results, risk factors, and the use of capital for research, development, commercialization and working capital.
Recent filings include Form 8-K reports for financial results, Regulation FD presentations, executive compensation actions and material agreements, as well as registration statements for common stock, pre-funded warrants and common stock warrants. Proxy materials describe stockholder voting matters, charter-related proposals, board governance and compensation disclosures.
BioRestorative Therapies, Inc. reporting persons led by Auctus Fund, LLC amend their Schedule 13G to show collective beneficial ownership of 2,699,470 shares of Common Stock, representing 9.9% of the class. This total includes 1,155,914 shares owned and 1,543,556 shares issuable upon exercise of warrants.
The filing cites 25,748,170 shares outstanding as of March 23, 2026 (per the issuer's 10-Q) as the base for the percentage calculation. The warrants contain a 9.99% blocker provision that prevents exercise beyond that threshold and excludes 1,498,718 warrant shares from current beneficial ownership calculations.
BioRestorative Therapies, Inc. reported first‑quarter 2026 revenue of $23,170, similar to the prior year’s $25,000, with new product sales of its BioX cosmetic line partly offsetting lower royalty income. Operating expenses fell sharply, with research and development at $1.93M and general and administrative at $1.48M, helping narrow the net loss to $2.15M from $5.34M a year earlier.
Results were boosted by a non‑cash gain of $1.22M from remeasuring and reclassifying warrant liabilities to equity. At March 31, 2026, cash and cash equivalents were $3.11M and marketable securities were $0.48M, with working capital of $2.19M. The company completed a Rodman public offering with gross proceeds of $5.0M, providing $4.44M of net financing inflows in the quarter.
Management nonetheless states that recurring losses, negative operating cash flow of $3.81M, and limited resources raise “substantial doubt” about its ability to continue as a going concern without additional capital. The company also received a Nasdaq notice on March 26, 2026 for failing to meet the $1.00 minimum bid price requirement and is evaluating options, including a potential reverse stock split. Material weaknesses in internal control over financial reporting identified in 2025 remain unresolved, though remediation efforts are underway.
BioRestorative Therapies, Inc. reported that its Compensation Committee approved cash bonuses for executive officers for the year ended December 31, 2025, and presented an updated Summary Compensation Table.
For 2025, CEO Lance Alstodt received salary of $596,666, a discretionary cash bonus of $300,000 and total compensation of $2,409,167. VP of Research and Development Francisco Silva received salary of $566,666, a $287,500 discretionary bonus and total compensation of $2,322,916. CFO Robert Kristal received salary of $343,750, a $140,000 discretionary bonus and total compensation of $801,750. The bonuses relate to 2025 services and are to be paid in 2026.
Registration covers up to 15,285,715 shares of common stock underlying outstanding warrants. This prospectus registers 14,285,715 shares issuable upon exercise of Common Stock Warrants (exercise price $0.35) and 1,000,000 shares issuable upon exercise of Placement Agent Warrants (exercise price $0.4375), each exercisable until February 13, 2031. The filing states 25,478,170 shares outstanding as of April 28, 2026 and a post‑exercise share count of up to 40,763,885 assuming full exercise. The company estimates gross proceeds of $5,437,500 if all warrants are exercised for cash and discloses a cashless exercise feature if registration is not effective.
BioRestorative Therapies, Inc. filed Amendment No. 1 to its Post-Effective Amendment No. 1 to the Form S-1 registration statement (Registration No. 333-293322) on April 27, 2026. This amendment is exhibit-only and files a revised opinion of counsel as Exhibit 5; the prospectus and remaining Part II are unchanged.
The filing lists the registrant's principal office in Melville, New York, identifies Nevada as the state of incorporation, and references multiple exhibits and agreements incorporated by reference, including an At the Market Offering Agreement dated November 6, 2024.
BioRestorative Therapies, Inc. furnished an updated corporate presentation that may be used at conferences and investor meetings. The deck is available on the company’s website and is attached as Exhibit 99.1.
The presentation is furnished under a disclosure item and is not deemed filed or subject to Section 18 liability, nor automatically incorporated into other Securities Act or Exchange Act filings.
BioRestorative Therapies, Inc. files a Post-Effective Amendment to its Form S-1 to register up to 15,285,715 shares of common stock issuable upon exercise of outstanding warrants issued in February 2026.
The amendment incorporates the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and updates offering details for the 14,285,715 Common Stock Warrants (exercise price $0.35) and 1,000,000 Placement Agent Warrants (exercise price $0.4375), exercisable through February 13, 2031. The prospectus notes going-concern disclosure and states estimated gross proceeds of $5,437,500 if all warrants are exercised for cash.
BioRestorative Therapies, Inc. is asking stockholders to approve an amendment increasing authorized common shares from 75,000,000 to 1,500,000,000 and to allow adjournment of the special meeting if more proxies are needed. As of April 6, 2026, 25,478,170 common shares were outstanding.
The company cites future capital raising for clinical trials of BRTX-100, its ThermoStem program, biocosmeceuticals development, employee plans, and securities conversions as key uses for additional shares. It warns that future issuances could dilute existing holders’ ownership and notes it currently lacks preemptive rights for stockholders.
The proxy also discloses that the company received a Nasdaq notice on March 26, 2026 for not meeting the $1.00 minimum bid requirement and has until September 22, 2026 to regain compliance. The board highlights existing anti-takeover provisions but states it has no current plans to use additional shares or preferred stock to entrench management.
BioRestorative Therapies, Inc. is asking stockholders to approve an amendment to increase authorized common shares from 75,000,000 to 1,500,000,000 at a Special Meeting on May 26, 2026. The Board also seeks authority to adjourn the meeting to solicit additional proxies if needed. The record date for voting is April 6, 2026. The proxy materials and the 2025 Form 10-K will be made available to stockholders by April 13, 2026. The Board states it has no definitive plans to issue the newly authorized shares but says additional shares would permit future capital raises and other corporate uses. The company disclosed a Nasdaq notice of noncompliance with the $1.00 minimum bid price and has until September 22, 2026 (an initial 180-day cure period from a March 26, 2026 notice) to regain compliance.